RAD51C germline mutations found in Spanish site-specific breast cancer and breast-ovarian cancer families

Breast Cancer Research and Treatment

Volumn 147, Issue 1, 2014, Pages 133-143

  Blanco, Ana ^a   Gutiérrez Enríquez, Sara ^b   Santamariña, Marta ^a   Montalban, Gemma ^b   Bonache, Sandra ^b,c   Balmaña, Judith ^d   Carracedo, Ángel ^a   Diez, Orland ^b,d   Vega, Ana ^a  

^a UNIVERSITY OF SANTIAGO DE COMPOSTELA   (Spain)

^b UNIVERSITAT AUTÒNOMA DE BARCELONA   (Spain)

^c HOSPITAL UNIVERSITARI VALL D HEBRON   (Spain)

^d HOSPITAL UNIVERSITARI VALL D HEBRON   (Spain)

Author keywords

BRCA1 2 negative; Germline mutation; Hereditary breast and or ovarian cancer; RAD51C

Indexed keywords

BRCA1 PROTEIN; BRCA2 PROTEIN; COMPLEMENTARY DNA; BRCA1 PROTEIN, HUMAN; BRCA2 PROTEIN, HUMAN; DNA BINDING PROTEIN; RAD51C PROTEIN, HUMAN;

ADULT; ARTICLE; BREAST CANCER; CANCER FAMILY; CANCER SUSCEPTIBILITY; COMPUTER MODEL; CONTROLLED STUDY; DNA DETERMINATION; ETHNIC GROUP; FEMALE; GENETIC VARIABILITY; GERM LINE; HETEROZYGOTE; HUMAN; MAJOR CLINICAL STUDY; MUTATIONAL ANALYSIS; NUCLEOTIDE SEQUENCE; OVARY CANCER; PRIORITY JOURNAL; PROTEIN ANALYSIS; PROTEIN PROCESSING; RAD51C GENE; SPANISH; TUMOR GENE; BREAST NEOPLASMS; FAMILY; FOLLOW UP; GENETIC PREDISPOSITION; GENETICS; GERMLINE MUTATION; MIDDLE AGED; OVARIAN NEOPLASMS; PROGNOSIS; SPAIN;

ADULT; BRCA1 PROTEIN; BRCA2 PROTEIN; BREAST NEOPLASMS; DNA-BINDING PROTEINS; FAMILY; FEMALE; FOLLOW-UP STUDIES; GENETIC PREDISPOSITION TO DISEASE; GERM-LINE MUTATION; HUMANS; MIDDLE AGED; OVARIAN NEOPLASMS; PROGNOSIS; SPAIN;

EID: 84905962729     PISSN: 01676806     EISSN: 15737217     Source Type: Journal    
DOI: 10.1007/s10549-014-3078-4     Document Type: Article

References (37)

1. Peto J, Collins N, Barfoot R et al (1999) Prevalence of BRCA1 and BRCA2 gene mutations in patients with early-onset breast cancer. J Natl Cancer Inst 91:943-949
2. Miki Y, Swensen J, Shattuck-Eidens D et al (1994) A strong candidate for the breast and ovarian cancer susceptibility gene BRCA1 . Science 266:66-71
3. Wooster R, Bignell G, Lancaster J et al (1995) Identification of the breast cancer susceptibility gene BRCA2. Nature 378:789-792. doi:10.1038/378789a0
4. Nichols KE, Malkin D, Garber JE et al (2001) Germ-line p53 mutations predispose to a wide spectrum of early-onset cancers. Cancer Epidemiol Biomark Prev 10:83-87
5. Pilarski R, Eng C (2004) Will the real Cowden syndrome please stand up (again)? Expanding mutational and clinical spectra of the PTEN hamartoma tumour syndrome. J Med Genet 41:323-326
6. Meijers-Heijboer H, van den Ouweland A, Klijn J et al (2002) Low-penetrance susceptibility to breast cancer due to CHEK2(*)1100-delC in noncarriers of BRCA1 or BRCA2 mutations. Nat Genet 31:55-59. doi:10.1038/ng879
7. Desrichard A, Bidet Y, Uhrhammer N, Bignon Y-J (2011) CHEK2 contribution to hereditary breast cancer in non-BRCA families. Breast Cancer Res 13:R119. doi:10.1186/bcr3062
8. Swift M, Reitnauer PJ, Morrell D, Chase CL (1987) Breast and other cancers in families with ataxia-telangiectasia. N Engl J Med 316:1289-1294. doi:10.1056/NEJM198705213162101
9. Thorstenson YR, Roxas A, Kroiss R et al (2003) Contributions of ATM mutations to familial breast and ovarian cancer. Cancer Res 63:3325-3333
10. Seal S, Thompson D, Renwick A et al (2006) Truncating mutations in the Fanconi anemia J gene BRIP1 are low-penetrance breast cancer susceptibility alleles. Nat Genet 38:1239-1241. doi:10.1038/ng1902
11. Rahman N, Seal S, Thompson D et al (2007) PALB2, which encodes a BRCA2-interacting protein, is a breast cancer susceptibility gene. Nat Genet 39:165-167. doi:10.1038/ng1959
12. Takata M, Sasaki MS, Tachiiri S et al (2001) Chromosome instability and defective recombinational repair in knockout mutants of the five Rad51 paralogs. Mol Cell Biol 21:2858-2866. doi:10.1128/MCB.21.8.2858-2866.2001
13. Masson JY, Tarsounas MC, Stasiak AZ et al (2001) Identification and purification of two distinct complexes containing the five RAD51 paralogs. Genes Dev 15:3296-3307. doi:10.1101/gad.947001
14. Dray E, Etchin J, Wiese C et al (2010) Enhancement of RAD51 recombinase activity by the tumor suppressor PALB2. Nat Struct Mol Biol 17:1255-1259. doi:10.1038/nsmb.1916
15. Meindl A, Hellebrand H, Wiek C et al (2010) Germline mutations in breast and ovarian cancer pedigrees establish RAD51C as a human cancer susceptibility gene. Nat Genet 42:410-414. doi:10.1038/ng.569
16. Vaz F, Hanenberg H, Schuster B et al (2010) Mutation of the RAD51C gene in a Fanconi anemia-like disorder. Nat Genet 42:406-409. doi:10.1038/ng.570
17. Pelttari LM, Heikkinen T, Thompson D et al (2011) RAD51C is a susceptibility gene for ovarian cancer. Hum Mol Genet 20:3278-3288. doi:10.1093/hmg/ddr229
18. Vuorela M, Pylkäs K, Hartikainen JM et al (2011) Further evidence for the contribution of the RAD51C gene in hereditary breast and ovarian cancer susceptibility. Breast Cancer Res Treat 130:1003-1010. doi:10.1007/s10549-011- 1677-x
19. Walsh T, Casadei S, Lee MK et al (2011) Mutations in 12 genes for inherited ovarian, fallopian tube, and peritoneal carcinoma identified by massively parallel sequencing. Proc Natl Acad Sci USA 108:18032-18037. doi:10.1073/pnas.1115052108
20. Thompson ER, Boyle SE, Johnson J et al (2012) Analysis of RAD51C germline mutations in high-risk breast and ovarian cancer families and ovarian cancer patients. Hum Mutat 33:95-99. doi:10.1002/humu.21625
21. Loveday C, Turnbull C, Ruark E et al (2012) Germline RAD51C mutations confer susceptibility to ovarian cancer. Nat Genet 44:475-476. doi:10.1038/ng.2224
22. Zheng Y, Zhang J, Hope K et al (2010) Screening RAD51C nucleotide alterations in patients with a family history of breast and ovarian cancer. Breast Cancer Res Treat 124:857-861. doi:10.1007/s10549-010-1095-5
23. Akbari MR, Tonin P, Foulkes WD et al (2010) RAD51C germline mutations in breast and ovarian cancer patients. Breast Cancer Res 12:404. doi:10.1186/bcr2619
24. Wong MW, Nordfors C, Mossman D et al (2011) BRIP1, PALB2, and RAD51C mutation analysis reveals their relative importance as genetic susceptibility factors for breast cancer. Breast Cancer Res Treat 127:853-859. doi:10.1007/s10549-011-1443-0
25. Pang Z, Yao L, Zhang J et al (2011) RAD51C germline mutations in Chinese women with familial breast cancer. Breast Cancer Res Treat 129:1019-1020. doi:10.1007/s10549-011-1574-3
26. Clague J, Wilhoite G, Adamson A et al (2011) RAD51C germline mutations in breast and ovarian cancer cases from high-risk families. PLoS ONE 6:e25632. doi:10.1371/journal.pone.0025632
27. De Leeneer K, Van Bockstal M, De Brouwer S et al (2012) Evaluation of RAD51C as cancer susceptibility gene in a large breast-ovarian cancer patient population referred for genetic testing. Breast Cancer Res Treat 133:393-398. doi:10.1007/s10549-012-1998-4
28. Lu W, Wang X, Lin H et al (2012) Mutation screening of RAD51C in high-risk breast and ovarian cancer families. Fam Cancer 11:381-385. doi:10.1007/s10689-012-9523-9
29. Romero A, Pérez-Segura P, Tosar A et al (2011) A HRM-based screening method detects RAD51C germ-line deleterious mutations in Spanish breast and ovarian cancer families. Breast Cancer Res Treat 129:939-946. doi:10.1007/s10549-011-1543-x
30. Osorio A, Endt D, Fernández F et al (2012) Predominance of pathogenic missense variants in the RAD51C gene occurring in breast and ovarian cancer families. Hum Mol Genet 21:2889-2898. doi:10.1093/hmg/dds115
31. Coulet F, Fajac A, Colas C et al (2013) Germline RAD51C mutations in ovarian cancer susceptibility. Clin Genet 83:332-336. doi:10.1111/j.1399-0004. 2012.01917.x
32. Silvestri V, Rizzolo P, Falchetti M et al (2011) Mutation screening of RAD51C in male breast cancer patients. Breast Cancer Res 13:404. doi:10.1186/bcr2823
33. Kushnir A, Laitman Y, Shimon SP et al (2012) Germline mutations in RAD51C in Jewish high cancer risk families. Breast Cancer Res Treat 136:869-874. doi:10.1007/s10549-012-2317-9
34. Schnurbein G, Hauke J, Wappenschmidt B et al (2013) RAD51C deletion screening identifies a recurrent gross deletion in breast cancer and ovarian cancer families. Breast Cancer Res 15:R120. doi:10.1186/bcr3589
35. Pennington KP, Walsh T, Harrell MI et al (2014) Germline and somatic mutations in homologous recombination genes predict platinum response and survival in ovarian, fallopian tube, and peritoneal carcinomas. Clin Cancer Res 20:764-775. doi:10.1158/1078-0432.CCR-13-2287
36. Cunningham JM, Cicek MS, Larson NB et al (2014) Clinical characteristics of ovarian cancer classified by BRCA1, BRCA2, and RAD51C status. Sci Rep 4:4026. doi:10.1038/srep04026
37. Somyajit K, Subramanya S, Nagaraju G (2012) Distinct roles of FANCO/RAD51C protein in DNA damage signaling and repair: implications for Fanconi anemia and breast cancer susceptibility. J Biol Chem 287:3366-3380. doi:10.1074/jbc.M111.311241